Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 7/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860615 | 0.92 | SERPINE1 (0.53) | SERPINE1PLA2G2APPARGF2RL3CYP1A2 | |
| SCHEMBL3845107 | 0.89 | SERPINE1 (0.58) | SERPINE1PLA2G2APPARGPTGES2PTGES | |
| SCHEMBL5097375 | 0.88 | PLA2G2A (0.50) | SERPINE1PLA2G2APTGES2PTGES | |
| SCHEMBL5106347 | 0.84 | PTGES2 (0.54) | SERPINE1PLA2G2APTGES2PTGES | |
| SCHEMBL3857761 | 0.83 | SERPINE1 (0.51) | SERPINE1PLA2G2APPARGPTGES2PTGES | |
| SCHEMBL4937642 | 0.82 | SERPINE1 (0.65) | SERPINE1PLA2G2APPARGPTGES2PTGES | |
| Tiplasinin SCHEMBL29448190 | 0.77 | SERPINE1 (1.00) | SERPINE1PLA2G2A | |
| Tiplasinin SCHEMBL3052065 | 0.77 | SERPINE1 (1.00) | SERPINE1PLA2G2A | |
| SCHEMBL5100345 | 0.77 | PLA2G2A (0.48) | PLA2G2A | |
| SCHEMBL5492993 | 0.75 | SERPINE1 (0.56) | SERPINE1PLA2G2APPARGPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2008097897-A9 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1(PAI-1) | WYETH CORP (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008097897-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1(PAI-1) | WYETH (US) | 2008-08-14 | — | — | WO | claimed |
| US-20080188540-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-08-07 | — | — | US | claimed |
| US-20080188543-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-08-07 | — | — | US | claimed |
| US-7368471-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-05-06 | — | — | US | claimed |
| EP-1844771-A2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | Wyeth (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| EP-1397130-B1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-27 | — | — | US | claimed |
| US-7074817-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-11 | — | — | US | claimed |
| EP-1397130-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | claimed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | claimed |
| WO-2003000253-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| US-7459478-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1397130-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | disclosed |
| WO-2003000253-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885PLA2G2A 1905/4885PPARG 2529/4885 |
| US-20080188540-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, TFPI, MMP1 | SERPINE1 1/4885PLA2G2A 755/4885PPARG 1512/4885 |
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, TFPI, F12 | SERPINE1 1/4885PLA2G2A 582/4885PPARG 481/4885 |
| US-20080188543-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, MMP1, TFPI | SERPINE1 1/4885PLA2G2A 757/4885PPARG 1649/4885 |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F12 | SERPINE1 1/4885PLA2G2A 576/4885PPARG 483/4885 |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | TFPI, SERPINE1, PLAT | SERPINE1 2/4885PLA2G2A 538/4885PPARG 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.